My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 518

    1.

    Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications.

    Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Nakatani Y, Ohtoshi K, Hayaishi-Okano R, Kosugi K, Hori M, Yamasaki Y.

    Diabetes Care. 2005 Nov;28(11):2716-21.PMID: 16249545 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes.

    Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, Umayahara Y, Kosugi K, Yamasaki Y.

    Atherosclerosis. 2009 May;204(1):288-92. Epub 2008 Sep 2.PMID: 18926539 [PubMed - indexed for MEDLINE]Related articles

    3.

    Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients.

    Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, Yamasaki Y.

    Diab Vasc Dis Res. 2008 Sep;5(3):190-7.PMID: 18777492 [PubMed - indexed for MEDLINE]Related articles

    4.

    Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.

    Gohda T, Tanimoto M, Moon JY, Gotoh H, Aoki T, Matsumoto M, Shibata T, Ohsawa I, Funabiki K, Tomino Y.

    Diabetes Res Clin Pract. 2008 Aug;81(2):196-201. Epub 2008 Jun 11.PMID: 18550199 [PubMed - indexed for MEDLINE]Related articles

    5.

    Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis.

    Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, Emoto M, Shoji T, Tamei H, Matsuki H, Sakurai S, Yamamoto Y, Yonekura H, Watanabe T, Yamamoto H, Nishizawa Y.

    Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2587-93. Epub 2005 Oct 13.PMID: 16224056 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.

    Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ.

    Diabetologia. 2006 Nov;49(11):2756-62. Epub 2006 Sep 13.PMID: 16969649 [PubMed - indexed for MEDLINE]Related articles

    7.

    Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.

    Nishizawa Y, Koyama H.

    J Ren Nutr. 2008 Jan;18(1):76-82. Review.PMID: 18089449 [PubMed - indexed for MEDLINE]Related articles

    8.

    Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes.

    Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP, Bierhaus A.

    Cardiovasc Diabetol. 2007 Mar 7;6:9.PMID: 17343760 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.

    Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, Natali A, Ferrannini E, Gastaldelli A.

    J Clin Endocrinol Metab. 2006 Nov;91(11):4628-34. Epub 2006 Aug 22.PMID: 16926247 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Association of soluble CD40 ligand with carotid atherosclerosis in Japanese type 1 diabetic patients.

    Katakami N, Kaneto H, Matsuhisa M, Miyatsuka T, Sakamoto K, Kawamori D, Yoshiuchi K, Nakamura Y, Kato K, Yamamoto K, Kosugi K, Hori M, Yamasaki Y.

    Diabetologia. 2006 Jul;49(7):1670-6. Epub 2006 May 12.PMID: 16752185 [PubMed - indexed for MEDLINE]Related articles

    11.

    Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease.

    Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Sato A, Imaizumi T.

    Diabetes Metab Res Rev. 2007 Jul;23(5):368-71.PMID: 17024691 [PubMed - indexed for MEDLINE]Related articles

    12.

    Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.

    Miura J, Yamagishi S, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, Iwamoto Y.

    J Diabetes Complications. 2003 Jan-Feb;17(1):16-21.PMID: 12505751 [PubMed - indexed for MEDLINE]Related articles

    13.

    Ultrasonographically assessed carotid atherosclerosis in Japanese type 2 diabetic patients: Role of nonesterified fatty acids.

    Taniguchi A, Nakai Y, Fukushima M, Teramura S, Hayashi R, Hama K, Marumoto K, Watanabe T, Yoshioka I, Sakaguchi K, Kishimoto H, Matsushita K, Okumura T, Tokuyama K, Nagasaka S, Sakai M.

    Metabolism. 2002 May;51(5):539-43.PMID: 11979382 [PubMed - indexed for MEDLINE]Related articles

    14.

    Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes.

    Berg TJ, Snorgaard O, Faber J, Torjesen PA, Hildebrandt P, Mehlsen J, Hanssen KF.

    Diabetes Care. 1999 Jul;22(7):1186-90.PMID: 10388987 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness.

    Choi KM, Yoo HJ, Kim HY, Lee KW, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH.

    Int J Cardiol. 2009 Feb 6;132(1):96-101. Epub 2008 Jan 10.PMID: 18190981 [PubMed - in process]Related articles

    16.

    Development of an ELISA for esRAGE and its application to type 1 diabetic patients.

    Sakurai S, Yamamoto Y, Tamei H, Matsuki H, Obata K, Hui L, Miura J, Osawa M, Uchigata Y, Iwamoto Y, Watanabe T, Yonekura H, Yamamoto H.

    Diabetes Res Clin Pract. 2006 Aug;73(2):158-65. Epub 2006 Feb 20.PMID: 16488505 [PubMed - indexed for MEDLINE]Related articles

    17.

    Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes.

    Suguro T, Watanabe T, Kodate S, Xu G, Hirano T, Adachi M, Miyazaki A.

    Clin Sci (Lond). 2008 Dec;115(11):327-34.PMID: 18338983 [PubMed - indexed for MEDLINE]Related articles

    18.

    Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.

    Tan KC, Chow WS, Tso AW, Xu A, Tse HF, Hoo RL, Betteridge DJ, Lam KS.

    Diabetologia. 2007 Sep;50(9):1819-25. Epub 2007 Jul 18.PMID: 17639302 [PubMed - indexed for MEDLINE]Related articles

    19.

    Increased basal levels of plasma nitric oxide in Type 2 diabetic subjects. Relationship to microvascular complications.

    Maejima K, Nakano S, Himeno M, Tsuda S, Makiishi H, Ito T, Nakagawa A, Kigoshi T, Ishibashi T, Nishio M, Uchida K.

    J Diabetes Complications. 2001 May-Jun;15(3):135-43.PMID: 11358682 [PubMed - indexed for MEDLINE]Related articles

    20.

    Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes.

    Yamamoto M, Yamaguchi T, Yamauchi M, Sugimoto T.

    Diabetes Care. 2009 Dec;32(12):2263-8. Epub 2009 Sep 14.PMID: 19752174 [PubMed - in process]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity